Profiel
Simon Cooper is currently Chief Medical Officer at Morphic Therapeutic, Inc. and Morphic Holding, Inc., both since 2024.
Former positions include Chief Medical Officer at Keros Therapeutics, Inc. from 2021 to 2024, Chief Medical Officer at Anokion US, Inc. from 2019 to 2021, Chief Medical Officer & Senior Vice President at Kadmon Holdings, Inc. in 2021, VP, Global Project Head-Immunology & Inflammation at Sanofi, and Global Program Medical Director at Novartis International AG from 2012 to 2014.
Education includes undergraduate studies at Newcastle University Medical School.
Actieve functies van Simon Cooper
| Bedrijven | Functie | Begin |
|---|---|---|
| MORC HOLD | Hoofd Techniek/Wetenschap/O&O | 19-03-2024 |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Hoofd Techniek/Wetenschap/O&O | 01-03-2024 |
Eerdere bekende functies van Simon Cooper
| Bedrijven | Functie | Einde |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 12-03-2024 |
| KADMON HOLDINGS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2021 |
Anokion US, Inc. | Hoofd Techniek/Wetenschap/O&O | 01-02-2021 |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Corporate Officer/Principal | 01-07-2014 |
| SANOFI | Corporate Officer/Principal | - |
Opleiding van Simon Cooper
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Health Technology |
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Discovers, develops and delivers transformative therapies for unmet medical needs | Health Technology |
Morphic Therapeutic, Inc.
Morphic Therapeutic, Inc. BiotechnologyHealth Technology Researches and develops small molecules to block transmembrane integrin receptors | Health Technology |
Keros Therapeutics, Inc.
Keros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics for muscle diseases | Health Technology |
Morphic Holding, Inc.
Morphic Holding, Inc. Pharmaceuticals: MajorHealth Technology Develops oral integrin drugs | Health Technology |
Newcastle University Medical School
Newcastle University Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anokion US, Inc. | Electronic Technology |
















